Detalhe da pesquisa
1.
Fixed-Duration Pirtobrutinib plus Venetoclax with or without Rituximab in Relapsed/Refractory CLL: Phase 1b BRUIN Trial.
Blood
; 2024 Jun 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38861666
2.
An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer.
Breast Cancer Res Treat
; 195(3): 275-287, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35915198
3.
Pharmacological Probes to Validate Biomarkers for Analgesic Drug Development.
Int J Mol Sci
; 23(15)2022 Jul 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-35955432
4.
A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors.
Invest New Drugs
; 39(5): 1284-1297, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33852104
5.
LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial.
Invest New Drugs
; 39(4): 1057-1071, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33624233
6.
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
Lancet Oncol
; 21(6): 763-775, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32353342
7.
Abemaciclib Does Not Have a Clinically Meaningful Effect on Pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 Substrates in Patients with Cancer.
Drug Metab Dispos
; 48(9): 796-803, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32581049
8.
Efficacy and safety of abemaciclib alone and with PI3K/mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic adenocarcinoma: A randomized controlled trial.
Cancer Med
; 12(20): 20353-20364, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37840530
9.
Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: Phase 1b study.
NPJ Breast Cancer
; 8(1): 118, 2022 Nov 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36335120
10.
IMI2-PainCare-BioPain-RCT1: study protocol for a randomized, double-blind, placebo-controlled, crossover, multi-center trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by peripheral nerve excitability testing (NET).
Trials
; 23(1): 163, 2022 Feb 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35183242
11.
IMI2-PainCare-BioPain-RCT2 protocol: a randomized, double-blind, placebo-controlled, crossover, multicenter trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by non-invasive neurophysiological measurements of human spinal cord and brainstem activity.
Trials
; 23(1): 739, 2022 Sep 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36064434
12.
Investigating the impact of target lesion selection on drug effect evaluation and tumour growth rate determination using tumour growth inhibition models: Example of malignant pleural mesothelioma patients treated with cisplatin alone or in combination with pemetrexed.
Eur J Pharm Sci
; 161: 105781, 2021 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33667665
13.
A Randomized Phase I Study of Abemaciclib in Chinese Patients with Advanced and/or Metastatic Cancers.
Target Oncol
; 16(2): 177-187, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33492568
14.
nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer.
Clin Breast Cancer
; 21(3): 181-190.e2, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33148479
15.
IMI2-PainCare-BioPain-RCT3: a randomized, double-blind, placebo-controlled, crossover, multi-center trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by electroencephalography (EEG).
Trials
; 22(1): 404, 2021 Jun 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34140041
16.
Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study.
Front Oncol
; 11: 810023, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-35223458
17.
Impact of tumour size measurement inter-operator variability on model-based drug effect evaluation.
Cancer Chemother Pharmacol
; 85(4): 817-825, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32170415
18.
A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer.
Clin Cancer Res
; 26(20): 5310-5319, 2020 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32694159
19.
Opportunities for Quantitative Translational Modeling in Oncology.
Clin Pharmacol Ther
; 108(3): 447-457, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32569424
20.
Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study.
Clin Cancer Res
; 26(21): 5609-5620, 2020 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32847933